Clear responder, partial responder, no responder — three different next protocols.
By Week 8, the protocol has stopped being theoretical. You have a follow-up IGF-1, a fasting insulin, a body composition delta, and a strength curve. The compounds either worked the way the mechanism predicted or they didn't — and the gap between "kept running it because hope is a strategy" and "read the labs and adjusted" is the difference between a recomp that finishes and a recomp that stalls.
The practitioner consensus is blunt: most non-responses on a GH-secretagogue muscle-gain stack are not the compound failing. They are the upstream physiology refusing to cooperate. IGF-1 is the most reliable proxy for overall GH status. If it moved, the pituitary is firing and the liver is converting. If it didn't move, you have a receptor problem, an insulin problem, or a pituitary that is exhausted from prior secretagogue exposure. Each of those three diagnostic categories gets a different next protocol.
What the labs are actually telling you
Read three numbers together: IGF-1 delta (baseline → Week 8), fasting insulin, and lean mass change. Cross-reference them.
A clear responder shows IGF-1 climbing into the mid-to-upper reference range (without breaching 350 ng/mL), fasting insulin holding under 8 mIU/L, and measurable lean tissue gain with visible fat loss in the abdominal/visceral compartment. The GH axis is intact, the liver is converting GH to IGF-1 efficiently, and peripheral receptors are sensitive. Your job here is layering, not switching.
A partial responder shows IGF-1 that climbed early and then flattened — the classic plateau curve. Body composition shifted but weakly, or shifted in one compartment (fat down) while the other (lean mass) lagged. The most common substrate-cited cause is pituitary desensitization from a single secretagogue running unopposed too long, or upstream insulin creep that began antagonizing the GH signal mid-cycle. GHRP-2 and GHRP-6 both cause prolactin and cortisol fluctuations that can blunt the second half of a cycle if dosing wasn't rotated.
A no responder shows IGF-1 essentially unchanged from baseline, or moved without body composition following. Three substrate-grounded causes dominate: (1) fasting insulin above 8 mIU/L at baseline that was missed — GH naturally antagonizes insulin, and an elevated baseline forces metabolic dysfunction instead of recomposition; (2) prior secretagogue abuse leaving the pituitary in a refractory state; (3) compromised mitochondria that cannot answer the AMPK and protein synthesis demands the GH axis is making. Each requires a different compound replacement, not a higher dose of the same one.
Scenario 1 — The clear responder: layer for compartment specificity
You earned the right to push. The Phase 1 GHRH + GHRP foundation stays. You add a compound that addresses whatever compartment is lagging.
| Compound | Dose | Route | Frequency | Evidence Tier | Notes |
|---|---|---|---|---|---|
| Tesamorelin | 1 mg | SubQ | 1×/day, 5 days/week | Clinical | Adds if visceral fat persists despite Phase 1 response. FDA-approved for visceral fat reduction. |
| 5-Amino-1MQ | 50–100 mg | Oral | Daily, fasted AM | Expert | NNMT inhibitor — promotes lipolysis and amplifies NAD+ availability for mitochondrial recomp. |
| Ipamorelin | 100–200 mcg | SubQ | Pre-bed, fasted | Expert | Cleanest nighttime GH pulse — no cortisol or prolactin spillover. Adds if pre-bed slot empty. |
Hold all other variables. The mistake at this stage is stacking three new compounds and losing the ability to attribute the next delta.
Scenario 2 — The partial responder: rotate, don't escalate
The instinct is to increase the dose of the compound that worked early. The substrate disagrees. Pituitary desensitization responds to mechanism rotation, not dose escalation. Move from amplifying GHRH at the receptor it already saturated to a stronger GHRH analog, and add a second-generation ghrelin-mimetic at a lower paired dose.
| Compound | Dose | Route | Frequency | Evidence Tier | Notes |
|---|---|---|---|---|---|
| Tesamorelin | 1 mg | SubQ | 1×/day, 5 days/week | Clinical | Replaces CJC-1295 (no DAC) for stronger GHRH-receptor amplification and superior visceral effect. |
| Hexarelin | [practitioner corpus thin on exact paired-stack dose — track and report] | SubQ | Short cycle only, AM | Expert | Strongest of the GHRP family; paired at lower doses with another GHRP for additional gains. Limit to short cycles to avoid further desensitization. |
| Fasting insulin recheck | — | — | At Week 9 | Clinical | If insulin has crept above 8 mIU/L mid-cycle, GH secretagogues are working against insulin sensitivity. Pause and address before continuing. |
If insulin has climbed mid-cycle, the partial response is the insulin signal. Pause the GH-axis push, run a 4-week metabolic reset (insulin sensitization phase), and re-enter with a cleaner baseline.
Scenario 3 — The no responder: fix the upstream lever before another GH compound
This is the scenario where stubbornness costs the most. The pituitary is not the problem. Run the diagnostic decision tree:
First, recheck fasting insulin. If it sits above 8 mIU/L, stop all GH secretagogues. The practitioner consensus is explicit: starting or continuing GH secretagogues against elevated baseline insulin pushes further into metabolic dysfunction. Address insulin first — Retatrutide (titrated up slowly, never combined with semaglutide or tirzepatide), or a metabolic reset protocol — then re-enter the GH axis with a clean baseline.
Second, screen for mitochondrial inflammation. Crushing fatigue, paradoxical exhaustion after exercise, or a CRP that didn't drop on Phase 1 all point here. The substrate is direct: AMPK activation in compromised mitochondria triggers an oxidative burst that depletes ATP. Before the next muscle-protocol attempt, run Methylene Blue 0.5–1 mg daily for 2–4 weeks to stabilize the electron transport chain, then layer MOTS-c 5 mg SubQ 3×/week. Add BPC-157 500 mcg/day if fatigue is dominant — it accelerates mitochondrial membrane repair.
Third, if both insulin and mitochondrial markers are clean, the diagnosis is pituitary exhaustion. Cycle off all secretagogues for a minimum of 4 weeks before any re-attempt. The pituitary does recover, but only when given an actual off-window.
| Failure mode | First-line correction | Re-entry window |
|---|---|---|
| Fasting insulin >8 mIU/L | Retatrutide titration OR metabolic reset; defer GH stack | 8–12 weeks |
| Mitochondrial inflammation / CRP elevated | Methylene Blue → MOTS-c → BPC-157 sequence | 12–16 weeks |
| Pituitary refractoriness | Full secretagogue washout | 4+ weeks |
What you should feel by Week 10
- Clear responder layered: continued strength climb, visceral compartment visibly tighter, sleep depth holding from the pre-bed Ipamorelin.
- Partial responder rotated: IGF-1 unstuck on Week 10 retest, second-half cycle producing the gains the first half didn't.
- No responder corrected: not body composition yet — energy floor lifting, baseline inflammation falling, the substrate for the next muscle-gain attempt being rebuilt.
What's NOT happening yet
- Not new lean mass on a no-responder protocol. You are repairing the upstream physiology that will allow the next push to work. Expecting hypertrophy here is the wrong scoreboard.
- Not a higher dose of the same secretagogue rescuing a plateau. Desensitization is a receptor problem, not a dose problem.
- Not combined GLP-1 agonists if insulin correction is part of the no-responder branch — one at a time, ever.
- Not IGF-1 above 350 ng/mL as a goal. Chronic elevation above 350 carries cancer-risk signal in the epidemiology. The win is the mid-to-upper reference range, sustained.
The labs are the protocol. Read them, rotate against them, and adjust.